New hope for cancer patients: drug targets wasting syndrome
NCT ID NCT07243379
First seen Nov 21, 2025 · Last updated Jun 17, 2026 · Updated 34 times
Summary
This study looks at how well a drug called nanocrystalline megestrol acetate works for cancer patients who have cachexia, a condition causing severe weight loss and appetite loss. About 495 adults with cancer and cachexia will take the drug and be monitored for up to 12 weeks. The main goal is to see if their appetite improves after 4 weeks, with secondary goals of checking for weight gain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF MALIGNANT TUMOR CACHEXIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital, Affiliated to Zhengzhou University
RECRUITINGZhengzhou, Henan, 45000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.